SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India’s arm concludes USFDA audit with three minor observations

31 Jan 2022 Evaluate

Granules India’s wholly-owned foreign subsidiary -- Granules Pharmaceuticals, Inc. (GPI) has concluded USFDA audit with three minor observations. GPI located in Chantilly, Virginia, USA had undergone a Preapproval Inspection (PAI) by the US Food and Drug Administration (USFDA) from January 24, 2022 to January 28, 2022. The audit is a PAI for two of its product applications filed from this facility.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

857.90 -5.45 (-0.63%)
08-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1887.95
Dr. Reddys Labs. 1348.70
Cipla 1431.65
Zydus Lifesciences 1149.00
Lupin 2457.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: